Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismSARS-CoV-2 antigen inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Triera Biosciences
0 Patents (Medical) associated with Triera Biosciences
100 Deals associated with Triera Biosciences
100 Translational Medicine associated with Triera Biosciences